Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don M Benson

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple MyelomaDon M Benson, Adam D Cohen, Sundar Jagannath, et al.
Cancers|May 14, 2022
Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional ExperienceJordan Nunnelee, Francesca Cottini, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Journal of Geriatric Oncology|August 29, 2020
Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignanciesJordon L Jaggers, Smith Giri, Heidi D Klepin, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 8, 2014
Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindredYvonne A Efebera, Amy Sturm, Elizabeth C Baack, et al.
Blood|October 4, 2012
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myelomaDon M Benson, Craig C Hofmeister, Swaminathan Padmanabhan, et al.
Archives of Hematology and Blood Diseases|January 10, 2022
Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT)Akshata Pandit, Lai Wei, Luis Bustamante, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 24, 2019
Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell TransplantationHassan Issa, Nidhi Sharma, Qiuhong Zhao, et al.
Leukemia & Lymphoma|May 18, 2023
Survival outcomes following autologous stem cell transplant with melphalan 140mg/m<sup>2</sup> versus 200mg/m<sup>2</sup> preparative regimens in patients with multiple myelomaNidhi Sharma, Evan Benson, Qiuhong Zhao, et al.
Journal of Clinical Medicine|October 14, 2022
Early versus Late Discontinuation of Maintenance Therapy in Multiple MyelomaJordan Nunnelee, Francesca Cottini, Qiuhong Zhao, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple MyelomaDon M Benson, Adam D Cohen, Sundar Jagannath, et al.
Cancers|May 14, 2022
Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional ExperienceJordan Nunnelee, Francesca Cottini, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Journal of Geriatric Oncology|August 29, 2020
Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignanciesJordon L Jaggers, Smith Giri, Heidi D Klepin, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 8, 2014
Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindredYvonne A Efebera, Amy Sturm, Elizabeth C Baack, et al.
Blood|October 4, 2012
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myelomaDon M Benson, Craig C Hofmeister, Swaminathan Padmanabhan, et al.
Archives of Hematology and Blood Diseases|January 10, 2022
Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT)Akshata Pandit, Lai Wei, Luis Bustamante, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 24, 2019
Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell TransplantationHassan Issa, Nidhi Sharma, Qiuhong Zhao, et al.
Leukemia & Lymphoma|May 18, 2023
Survival outcomes following autologous stem cell transplant with melphalan 140mg/m<sup>2</sup> versus 200mg/m<sup>2</sup> preparative regimens in patients with multiple myelomaNidhi Sharma, Evan Benson, Qiuhong Zhao, et al.
Journal of Clinical Medicine|October 14, 2022
Early versus Late Discontinuation of Maintenance Therapy in Multiple MyelomaJordan Nunnelee, Francesca Cottini, Qiuhong Zhao, et al.
Pageof 11